{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:29:15Z","timestamp":1782912555946,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High-Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-116"],"award-info":[{"award-number":["2022-PUMCH-B-116"]}]},{"name":"National High-Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-127"],"award-info":[{"award-number":["2022-PUMCH-B-127"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2411504"],"award-info":[{"award-number":["2023YFC2411504"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2402305"],"award-info":[{"award-number":["2022YFC2402305"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2411502"],"award-info":[{"award-number":["2023YFC2411502"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Peking Union Medical College Hospital Talent Cultivation Program","award":["No.UBJ04712"],"award-info":[{"award-number":["No.UBJ04712"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-025-01903-9","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T15:43:38Z","timestamp":1754322218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Multimodal deep learning model for prognostic prediction in cervical cancer receiving definitive radiotherapy: a multi-center study"],"prefix":"10.1038","volume":"8","author":[{"given":"Weiping","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chulong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongguang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"1903_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA: A Cancer J. Clin."},{"key":"1903_CR2","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han, B. et al. Cancer incidence and mortality in China, 2022. J. Natl Cancer Cent. 4, 47\u201353 (2024).","journal-title":"J. Natl Cancer Cent."},{"key":"1903_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70269","volume":"13","author":"Z Zeng","year":"2024","unstructured":"Zeng, Z. et al. Weekly Image Guidance in patients with cervical cancer treated with intensity-modulated radiation therapy: results of a large cohort study. Cancer Med. 13, e70269 (2024).","journal-title":"Cancer Med."},{"key":"1903_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ygyno.2018.09.024","volume":"151","author":"W Wang","year":"2018","unstructured":"Wang, W. et al. Image-guided, intensity-modulated radiation therapy in definitive radiotherapy for 1433 patients with cervical cancer. Gynecol. Oncol. 151, 444\u2013448 (2018).","journal-title":"Gynecol. Oncol."},{"key":"1903_CR5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1470-2045(20)30753-1","volume":"22","author":"R P\u00f6tter","year":"2021","unstructured":"P\u00f6tter, R. et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 22, 538\u2013547 (2021).","journal-title":"Lancet Oncol."},{"key":"1903_CR6","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"D Lorusso","year":"2024","unstructured":"Lorusso, D. et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 404, 1321\u20131332 (2024).","journal-title":"Lancet"},{"key":"1903_CR7","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","volume":"403","author":"D Lorusso","year":"2024","unstructured":"Lorusso, D. et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet 403, 1341\u20131350 (2024).","journal-title":"Lancet"},{"key":"1903_CR8","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(24)01438-7","volume":"404","author":"M McCormack","year":"2024","unstructured":"McCormack, M. et al. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. Lancet 404, 1525\u20131535 (2024).","journal-title":"Lancet"},{"key":"1903_CR9","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1200\/JCO.19.00674","volume":"37","author":"SCS da Costa","year":"2019","unstructured":"da Costa, S. C. S. et al. Neoadjuvant chemotherapy with cisplatin and gemcitabine followed by chemoradiation versus chemoradiation for locally advanced cervical cancer a randomized phase II trial. J. Clin. Oncol. 37, 3124\u20133131 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1903_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ygyno.2018.10.026","volume":"152","author":"K Matsuo","year":"2019","unstructured":"Matsuo, K. et al. Validation of the 2018 FIGO cervical cancer staging system. Gynecol. Oncol. 152, 87\u201393 (2019).","journal-title":"Gynecol. Oncol."},{"key":"1903_CR11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ygyno.2020.03.027","volume":"157","author":"PW Grigsby","year":"2020","unstructured":"Grigsby, P. W. et al. FIGO 2018 staging criteria for cervical cancer: impact on stage migration and survival. Gynecol. Oncol. 157, 639\u2013643 (2020).","journal-title":"Gynecol. Oncol."},{"key":"1903_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13014-019-1355-4","volume":"14","author":"J Fu","year":"2019","unstructured":"Fu, J. et al. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer. Radiat. Oncol. J. 14, 146 (2019).","journal-title":"Radiat. Oncol. J."},{"key":"1903_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-018-1197-5","volume":"13","author":"K Hu","year":"2018","unstructured":"Hu, K. et al. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy. Radiat. Oncol. 13, 249 (2018).","journal-title":"Radiat. Oncol."},{"key":"1903_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.870670","volume":"12","author":"Q Meng","year":"2022","unstructured":"Meng, Q. et al. Nomograms predicting survival of cervical cancer patients treated with concurrent chemoradiotherapy based on the 2018 FIGO staging system. Front. Oncol. 12, 870670 (2022).","journal-title":"Front. Oncol."},{"key":"1903_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ygyno.2019.09.003","volume":"155","author":"W Wang","year":"2019","unstructured":"Wang, W. et al. Posttreatment squamous cell carcinoma antigen predicts treatment failure in patients with cervical squamous cell carcinoma treated with concurrent chemoradiotherapy. Gynecol. Oncol. 155, 224\u2013228 (2019).","journal-title":"Gynecol. Oncol."},{"key":"1903_CR16","doi-asserted-by":"publisher","first-page":"e0214498","DOI":"10.1371\/journal.pone.0214498","volume":"14","author":"W Wang","year":"2019","unstructured":"Wang, W. et al. Nomograms predicting survival and patterns of failure in patients with cervical cancer treated with concurrent chemoradiotherapy: a special focus on lymph nodes metastases. PLoS ONE 14, e0214498 (2019).","journal-title":"PLoS ONE"},{"key":"1903_CR17","doi-asserted-by":"publisher","first-page":"110463","DOI":"10.1016\/j.radonc.2024.110463","volume":"199","author":"J Marsilla","year":"2024","unstructured":"Marsilla, J. et al. A T2-weighted MRI-based radiomic signature for disease-free survival in locally advanced cervical cancer following chemoradiation: an international, multicentre study. Radiother. Oncol. 199, 110463 (2024).","journal-title":"Radiother. Oncol."},{"key":"1903_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11917-3","volume":"24","author":"H Liu","year":"2024","unstructured":"Liu, H. et al. Development and validation of a 18F-FDG PET\/CT radiomics nomogram for predicting progression free survival in locally advanced cervical cancer: a retrospective multicenter study. BMC Cancer 24, 150 (2024).","journal-title":"BMC Cancer"},{"key":"1903_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00261-022-03665-4","volume":"48","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. MRI-based radiomics for pretreatment prediction of response to concurrent chemoradiotherapy in locally advanced cervical squamous cell cancer. Abdom. Radio. 48, 367\u2013376 (2023).","journal-title":"Abdom. Radio."},{"key":"1903_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.acra.2022.08.002","volume":"30","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Nomograms combining clinical and imaging parameters to predict recurrence and disease-free survival after concurrent chemoradiotherapy in patients with locally advanced cervical cancer. Acad. Radio. 30, 499\u2013508 (2023).","journal-title":"Acad. Radio."},{"key":"1903_CR21","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s11547-022-01482-9","volume":"127","author":"R Autorino","year":"2022","unstructured":"Autorino, R. et al. Radiomics-based prediction of two-year clinical outcome in locally advanced cervical cancer patients undergoing neoadjuvant chemoradiotherapy. Radio. Med. 127, 498\u2013506 (2022).","journal-title":"Radio. Med."},{"key":"1903_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/1471-0528.17285","volume":"130","author":"K Ren","year":"2022","unstructured":"Ren, K. et al. Treatment planning computed tomography radiomics for predicting treatment outcomes and haematological toxicities in locally advanced cervical cancer treated with radiotherapy: a retrospective cohort study. BJOG 130, 222\u2013230 (2022).","journal-title":"BJOG"},{"key":"1903_CR23","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.brachy.2023.06.004","volume":"22","author":"C Small","year":"2023","unstructured":"Small, C. et al. A general framework to develop a radiomic fingerprint for progression-free survival in cervical cancer. Brachytherapy 22, 728\u2013735 (2023).","journal-title":"Brachytherapy"},{"key":"1903_CR24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s00066-022-01900-x","volume":"198","author":"S Pedraza","year":"2022","unstructured":"Pedraza, S. et al. The value of metabolic parameters and textural analysis in predicting prognosis in locally advanced cervical cancer treated with chemoradiotherapy. Strahlenther. Onkol. 198, 792\u2013801 (2022).","journal-title":"Strahlenther. Onkol."},{"key":"1903_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.108593","volume":"177","author":"W Xin","year":"2024","unstructured":"Xin, W. et al. Machine learning-based radiomics for predicting outcomes in cervical cancer patients undergoing concurrent chemoradiotherapy. Comput. Biol. Med. 177, 108593 (2024).","journal-title":"Comput. Biol. Med."},{"key":"1903_CR26","doi-asserted-by":"publisher","first-page":"102217","DOI":"10.1016\/j.inffus.2023.102217","volume":"105","author":"K Bayoudh","year":"2024","unstructured":"Bayoudh, K. A survey of multimodal hybrid deep learning for computer vision: architectures, applications, trends, and challenges. Inf. Fusion 105, 102217 (2024).","journal-title":"Inf. Fusion"},{"key":"1903_CR27","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/s43018-023-00619-7","volume":"4","author":"DA Jaffray","year":"2023","unstructured":"Jaffray, D. A. et al. Harnessing progress in radiotherapy for global cancer control. Nat. Cancer 4, 1228\u20131238 (2023).","journal-title":"Nat. Cancer"},{"key":"1903_CR28","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S1470-2045(23)00147-X","volume":"24","author":"LR Mileshkin","year":"2023","unstructured":"Mileshkin, L. R. et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 24, 468\u2013482 (2023).","journal-title":"Lancet Oncol."}],"updated-by":[{"DOI":"10.1038\/s41746-025-02204-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000}}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01903-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01903-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01903-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T06:36:22Z","timestamp":1766471782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01903-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1903"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-01903-9","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41746-025-02204-x","URL":"https:\/\/doi.org\/10.1038\/s41746-025-02204-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"503"}}